|Bid||0.00 x 1400|
|Ask||0.00 x 800|
|Day's Range||10.84 - 11.25|
|52 Week Range||6.26 - 17.35|
|Beta (3Y Monthly)||2.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.00|
Sangamo Therapeutics, Inc. , a genomic medicine company, announced today that management will present at the following investor conferences in September:
Sandy Macrae has been the CEO of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) since 2016. This analysis aims first to...
Sangamo (SGMO) delivered earnings and revenue surprises of 25.71% and -9.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) announces lower-than-expected earnings and revenues for the second quarter of 2019. It keeps its previously provided revenue guidance intact.
Sangamo's (SGMO) gene therapy candidate achieves encouraging factor VIII levels in an early-stage study evaluating it in hemophilia A patients.
On Friday last week, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced promising updated results from the Phase 1/2 ALTA trial.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...
Sangamo Therapeutics reported positive data on its gene therapy for hemophilia, and CannTrust Holdings received a noncompliance report from Canadian authorities.
Sangamo stock popped Monday after the biotech company unveiled promising results for its Pfizer-partnered gene therapy in hemophilia A treatment. Sangamo stock jumped as much as 16.9%.
Sangamo Therapeutics (NASDAQ:SGMO) stock was on the up and up to kick off the week as the business revealed that it has made some key forward progress in its gene therapy that is designed to treat hemophilia A.Source: Shutterstock The Richmond, Calif.-based business revealed on Friday -- along with its partner Pfizer (NYSE:PFE) -- updated data from its Phase I/II Alta study of SB-525, designed to treat the aforementioned blood ailment. The data was presented in Melbourne, Australia, which hosts the International Society on Thrombosis and Haemostasis congress.Sangamo and Pfizer highlighted data that showed, out of the four patients who were given the highest dose of 30 trillion vectors per kilogram, two of them rapidly experienced positive results. They attained normal and sustained levels of Factor VIII with no reported bleeding events or need to receive treatment with the factor for as long as 24 weeks.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe other two experienced Factor VIII activity kinetics that was consistent with the first two patients. Sangamo had presented interim data on eight patients that the biotechnology company treated with SB-525 in April, which indicated that the therapy was well-tolerated-the data also showed a dose-dependent increase in Factor VIII levels across the dosage cohorts.The California business was founded in 1995 and it focuses its treatments on helping patients with hemophilia and other genetic illnesses.SGMO stock is up about 3.5% on Monday following the news. More From InvestorPlace * 7 A-Rated Stocks to Buy for the Rest of 2019 * The 7 Top Small-Cap Stocks Of 2019 * 7 F-Rated Stocks to Sell for Summer * 7 Retail Stocks to Buy That Are Down in 2019 The post Sangamo Therapeutics News: SGMO Stock Surges on Gene Therapy Study appeared first on InvestorPlace.
Sangamo's stock price is surging after a pair of patients reported no bleeding events for as long as 24 weeks following treatment following investigational SB-525 gene therapy for severe hemophilia A.